Waters Corporation WAT launched an integrated high-resolution liquid chromatography mass spectrometry (LC-MS) system, namely the Waters BioAccord System with ACQUITY Premier. The BioAccord System ...
New LC-MS system delivers accurate and reproducible results for multi-attribute monitoring of biologics. Eliminates analyte-to-metal surface interactions greatly enhancing recovery of hard-to-detect ...
New Peptide MAM (multi-attribute method) workflow for the BioAccord LC-MS System monitors product quality attributes that can affect efficacy and safety of innovator drugs and biosimilars. End-to-end ...
Earlier in 2019, Waters Corporation announced their BioAccord LC-MS System for biopharmaceutical analysis. We spoke with John Gebler, PhD, Director of Strategic Business Development at Waters ...
New LC-MS system delivers accurate and reproducible results for multi-attribute monitoring of biologics. Eliminates analyte-to-metal surface interactions greatly enhancing recovery of hard-to-detect ...
Waters Corporation WAT launched an integrated high-resolution liquid chromatography mass spectrometry (LC-MS) system, namely the Waters BioAccord System with ACQUITY Premier. The BioAccord System ...
Waters Corporation (NYSE:WAT) today introduced the Waters™ BioAccord™ System with ACQUITY™ Premier, a combination of the Waters BioAccord System and the breakthrough ACQUITY Premier UPLC™ with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results